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Repairing the ‘Broken Middle’ of the Health 
Innovation Pathway:  
Exploring Diverse Practitioner Perspectives 
on the Emergence and Role of ‘Translational 
Medicine’ 
James Mittra 
The emergence of Translational Medicine (TM) as a potential solution to health 
innovation challenges has gained currency in scientifi c, clinical and policy discourses. 
Using interview data from key professionals involved in TM, this article explores 
diverse practitioner defi nitions and the multiple meanings ascribed to TM in the 
context of a purportedly broken R&D system and promissory visions and expectations 
built around new life science. It also begins to address some of the transformative 
impacts of TM on the broader institutional landscape for life science innovation, 
particularly the changes in traditional institutional boundaries. I conclude that in 
light of the multiple framings of TM, it might best be conceived as an institutional 
mechanism or process for co-ordinating multiple actors and complex activities in 
the new collaborative research and development contexts now demanded of the life 
sciences.  
Keywords: Translational Medicine, R&D, innovation
Introduction
Over the past 15-20 years Translational 
Medicine (TM) has become an omnipresent 
concept in the healthcare and life science 
sectors. It is employed as a broad, often 
ambiguous, metaphor to describe new 
ways of organising and funding R&D 
activities in the biosciences, with clinical 
application the primary goal. It is also used 
as a term that encompasses more tangible 
new technologies and approaches to drug 
development and clinical practice, such 
as biomarkers and associated diagnostic 
testing. TM is presented as a new solution to 
what is perceived to be a growing problem 
in health innovation: namely a widening 
gulf between basic science in the laboratory 
and its successful application in the clinic. 
Th e impetus for TM’s arrival and 
subsequent entrenchment in science, policy 
and clinical discourses (FDA, 2006; MRC, 
2008; Cooksey, 2006), appears to be the 
continuing problem that insuffi  cient novel 
therapies successfully transition from the lab 
to the clinic. What we might call the ‘broken 
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middle’ of therapeutic R&D has emerged 
as a powerful problem narrative that the 
pharmaceutical industry, in particular, 
believes is rooted in the complexity, risk 
and uncertainty of phase 2 clinical studies. 
Th is compounds a number of 21st century 
global health challenges (Tait et al., 2008), 
including industry’s continuing productivity 
crisis and perception of innovation defi cit 
(Mittra, 2008). Th e response has been 
unprecedented investment from both 
commercial and public sectors in various 
‘translational activities’ (individual projects, 
funding mechanisms, and new R&D units/
collaborative partnerships). Firms respond 
to the problem of mature product pipelines 
(Mittra et al., 2011) and an unsustainably 
high attrition rate of therapies in phase 2; 
while the public sector appears to push an 
expansive, downstream R&D agenda in 
biomedical sciences to deliver sustainable 
solutions for various public health 
challenges (BMJ, 2008).
Th e central aim of this article is to explore 
diff erent practitioner perspectives on the 
nature, role and value of TM in the context 
of these perceived challenges of the health 
innovation system, and consider some of 
the implications for the organisation of 
health R&D. How are diverse practitioner 
narratives being mobilised to frame ‘the 
problem’ of a broken health innovation 
pathway; what assumptions do these 
narratives make about the relationship 
between basic and applied science; and how 
has TM emerged as a potential panacea? 
While the primary focus is on the UK, where 
most of the primary data was collected, 
relevant developments in the United 
States are also considered, particularly the 
institutional and policy context of funding 
new translational initiatives. 
Th eoretically, the paper draws on the 
literature of hopes and expectations and 
the ways in which these shape and mobilise 
various resources in translational life 
science R&D (Borup et al., 2006, Martin 
et al., 2008), as well as a broad critical 
literature that has dealt with the changing 
relationship between basic and applied 
science, the limitations of the conventional 
linear or pathway model of innovation, and 
notional ideas of value in life science (Stokes, 
1997; Tait & Williams, 1999; Williams, 
2006; Birch, 2012). Th ese approaches are 
used initially to frame the ‘broken middle’ 
narrative and critically assess subsequent 
arguments that are strategically co-opted 
by diff erent actors and institutions to justify 
the need for new translational processes 
and activities.  At the end of the article, 
I will draw some conclusions about the 
broader impacts of this expansive and often 
opaque TM agenda on the organisational 
and institutional landscape for health R&D. 
Although the data reveal that the defi nition 
of TM is not unitary, and as a concept 
may often be chaotic and ephemeral, I 
conclude that it appears to be engendering 
real and potentially indelible changes in 
biomedicine and therefore should not 
simply be dismissed as mere hype.
Empirically, the paper draws on the 
author’s data from 20 in-depth semi-
structured interviews conducted with senior 
academic life scientists, academic clinicians, 
NHS directors, and representatives from the 
pharmaceutical industry and the policy/
regulatory community. Many respondents 
had dual roles and had worked in diff erent 
sectors. Most were either actively involved 
in projects or collaborative partnerships 
labelled as TM, or had clear professional 
interests at the interface between the 
laboratory and the clinic. 16 interviewees 
were based in the UK, while 4 were from 
outside the UK, including the Netherlands 
(1 interview) and the United States (3 
interviews). Th e UK-based interviews 
tended to focus on specifi c TM initiatives 
in the UK, whilst the US-based interviews 
tended to focus on more general issues 
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relevant to TM in both national and global 
contexts.  Although not a fully representative 
sample, which was never the aim of the 
project for which the data was collected, 
the interviews provide rich accounts of the 
salient features of TM; its various drivers, 
defi nitions and meanings; and the enduring 
impact on biomedical research in a number 
of diff erent research and clinical contexts. 
Furthermore, relevant policy documents 
and grey literature from the UK and United 
States are used to reveal some of the broader 
sectoral interests and values that circulate 
around TM.  
 Th e article is structured as follows. Th e 
fi rst section critically explores the notion 
of a ‘broken middle’ in health innovation, 
which foregrounds the emergence of TM 
and its subsequent framings in diff erent 
professional and institutional contexts. Th is 
section will highlight the diff erent drivers of 
TM and consider the broken middle of R&D, 
and its assumptions about the linear model 
of innovation and relationship between 
basic and applied science, as a recurrent 
‘problem narrative’ that presupposes TM as 
a viable solution. 
Next, interview data are used to explore 
practitioners’ discursive narratives for 
framing TM and its practical and conceptual 
boundaries. What do key actors consider 
the most salient features of TM and what 
are their long-term hopes and expectations 
for the fi eld? Th is section will identify both 
narrow and broad defi nitional frameworks 
for TM. Th e centrality of ‘biomarkers’ 
in contemporary discussions about the 
potential value of TM will then be explored. 
Th e ways in which practitioner narratives 
become structured around the value, benefi t 
and limitations of trying to reconfi gure the 
R&D pathway according to ‘translational’ 
principles will become evident in this 
section. 
In the conclusion, I will refl ect on 
some of the broader organisational and 
institutional changes engendered by 
TM and the multiple meanings diff erent 
actors and institutions have ascribed to 
it. Ultimately, TM will be presented as an 
institutional mechanism for coordinating 
multiple professions, knowledge domains 
and economic/scientifi c activities within 
new organisational contexts; a kind of 
‘social technology’ in Nelson and Sampat’s 
terminology (Nelson & Sampat, 2001).
The ‘Broken Middle of R&D’ 
Narrative and its Role in Shaping 
the Translational Medicine Agenda 
Th e emergence of TM in the mid 1990s as a 
set of diverse strategic initiatives to facilitate 
health innovation was engendered by 
growing concern that despite unprecedented 
investment in life sciences, coupled with 
the growth of scientifi c knowledge around 
the cellular and physiological mechanisms 
of disease, many promising therapeutic 
products in early stage drug development 
fail to make it to market. Furthermore, few 
new therapies that do make it through the 
regulatory system become widely adopted 
as the clinical standard (Milne, 2009). 
Th ere is a prevalent belief that healthcare 
innovation is stymied by a constellation 
of scientifi c, clinical, social, policy and 
regulatory challenges. An increasingly 
powerful and pervasive rhetoric in industry 
and policy circles is that between discovery 
and the clinic (specifi cally phase 2 R&D) 
many drugs fall into what some have 
labelled ‘the valley of death’, characterised 
by a chronic disconnect between the 
knowledge, fi ndings and expertise of 
research scientists in the lab and those of 
clinicians at the bedside (Nature, 2008). Th is 
problem, which presupposes a particular 
view of the historical relationship between 
bench and bedside and the very structure of 
the innovation pathway, has shaped certain 
expectations and hopes around TM. 
Science & Technology Studies 3/2013
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Th e Basic/Applied Science Distinction 
and Assumptions about the Conventional 
Health Innovation Pathway Model
Kraft (2013) argues that the ostensibly 
tenuous relationship between lab and clinic 
has long been viewed by policymakers as a 
barrier to therapeutic innovation and has 
become a key target for new interventionist 
strategies from all sectors involved in health 
innovation. Both industry and the public 
sector are embracing the philosophy and 
promissory visions of TM as a central 
strategy for driving improvement of the 
health innovation cycle, which is considered 
to be fundamentally broken (Mittra & 
Milne, 2013). However, a more sceptical 
literature has begun to question the novelty 
and underlying assumptions of TM and the 
purported notions of value and benefi t that 
resonate within an expectant biomedical 
research and clinical community (Birch, 
2012; Birch & Tyfi eld, 2012; Martin et al., 
2008). 
Furthermore, questions must be asked 
about the implicit assumption of a fi xed 
and linear health innovation pathway, and 
the conventional distinction between basic 
and applied research, which is couched 
within the rhetoric of a broken middle 
of R&D and the concept of ‘translation’ 
itself. Th e hopes and expectations that 
have been built around new life science 
and TM approaches, which are driving 
the organisation and management of 
institutional resources, may be based on 
unrealistic or untested assumptions both 
about the science and technology and the 
nature of R&D (Terwilliger & Goring, 2009). 
Stokes (1997) nicely critiqued the 
traditional linear model of innovation, and 
the conventional distinction made between 
basic and applied research, by looking at 
a number of historical examples, such as 
Pasteur’s work in microbiology, which was 
simultaneously basic and applied research. 
Th ere is also growing evidence to suggest 
that the past portrayal of therapeutic R&D as 
linear and one directional, in contrast to the 
now more dynamic and novel TM approach, 
never refl ected realities on the ground. For 
instance, Martin et al. (2008) have noted that 
historically the application of basic science 
never was the caricatured one-directional 
process often presented. Th e authors cite 
Lowry’s account of cancer therapies using 
interleukin 11, which required signifi cant 
contributions from both clinicians and 
patients (Lowry, 1997). Another example 
is Banting and Macleod’s 1922 discovery of 
insulin as a treatment for diabetes, which 
moved back-and-forth from animal models 
to fi rst-in-man studies and involved many 
of the interdisciplinary and cross-sector 
collaborations that are often heralded as the 
cornerstone of TM.  Furthermore, the very 
notion that a problem exists at the lab-clinic 
interface was recognised in the early 1970s, 
as Woolf (1974) noted in a New England 
Journal of Medicine editorial in 1974. 
Th e leitmotif of linearity in retrospective 
accounts of applied basic science does not 
seem to correspond to scientifi c practice, 
which begs the question of what is new in 
contemporary attempts to reconfi gure or fi x 
the lab-clinic interface.
Although health innovation is not the 
crude linear process that is often portrayed, 
as the basic and applied sciences are not 
temporally and spacially distinct as often 
assumed, the linear model is still routinely 
used to frame biomedical R&D. Th e linear 
stages of therapeutic R&D are perhaps more 
a representational artefact of the regulatory 
regime, which demands the presentation 
of research in distinct, sequential phases. 
Th is elides the parallel processes and 
heterogeneous actors and innovation 
networks that actually shape R&D, as 
described in detail by Hara (Hara, 2003). Th e 
concept of linearity, which is easily reifi ed 
through casual rhetoric of translational 
gaps in drug ‘pipelines’, therefore continues 
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to drive much R&D policy and management 
(Tait & Williams, 1999; Williams, 2006). 
An alternative to viewing innovation in 
these crude linear terms is to consider 
broader innovation value systems and the 
various feedback loops and contingencies 
that shape and infl uence individual value 
chains, as discussed recently by the author 
and others in Mastroeni et al. (2012). One 
interview respondent from the policy 
community captured this problem with the 
linear model when he stated:
I think one of the challenges in this 
whole area is that the linear model of 
drug development is overly simplistic 
and, whilst it had enormous strengths 
in persuading those in the Treasury as 
to where the gaps might be, in the real 
world scientifi c discovery or even thera-
peutic development is in no way as sim-
ple as that (POL1).
Th is tension between linear models of 
innovation, bench to bedside relations and 
the novelty of TM will become more apparent 
later when practitioner narratives on the 
role and scope of TM are explored. For now, 
I simply emphasise that discussions about 
basic and applied research; assumptions 
of linearity in R&D, and expectations that 
‘translation’ might fi x the problem of the 
broken middle are closely connected and 
foreground the many diff erent framings 
of TM as well as the institutional and 
organisational practices of those sectors 
involved in biomedical innovation.  
The Foundations of the 
‘Broken Middle’ Narrative
Arguments claiming there are translational 
gaps in the health innovation system tend 
to focus on specifi c hurdles and constraints 
along the conventionally understood 
‘bench-to-bedside continuum’, which 
makes it easy to slip into the casual rhetoric 
of a broken middle that can in principle 
be fi xed by TM. Hurdles that are routinely 
highlighted include not only cultural, 
institutional and economic barriers that can 
inhibit successful translation of discovery 
science into viable clinical products, but 
also more tangible challenges facing drug 
developers. Th ese include lack of suffi  cient 
effi  cacy and safety in phase 2 clinical 
studies, onerous and costly regulatory 
systems; rising R&D costs, patent expiry 
on blockbuster drugs with few products 
to replace them; and the organisational 
challenge of moving from small-molecule 
to life science-based R&D (Mittra, 2007).
Mature product pipelines and the 
diffi  culty of identifying viable business 
models for novel life science therapies 
appear to be contributing to industry’s 
growing anxiety about R&D and long-
term sustainability of blockbuster drug 
development. Although there is debate 
about the nature and extent of ‘innovation 
defi cit’ in the pharmaceutical industry - 
some authors ask if declining innovation 
is actually a myth (Schmid & Smith, 2005), 
and others maintain that reduction in R&D 
productivity is the result of a concentration 
of R&D eff orts in high risk research for 
unmet medical need, rather than a lack 
of innovation (Pamolli, 2011) – there is 
little doubt that companies believe that 
they are no longer producing suffi  cient 
high-value therapies to sustain growth. 
Furthermore, ‘productivity’ from in-
house R&D is evidently falling according 
to the bibliometric analysis conducted by 
Rafols et al. (2012). Th e so called genomics 
revolution has also yet to prove the panacea 
for industry woes and bring about a truly 
revolutionary era of biotechnology-based 
therapeutics (Kraft, 2004; Hopkins et al., 
2007). Data reveal that the number of new 
drug approvals has continued to decline 
since the mid-1990s, despite increasing 
James Mittra
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year-on-year investment in R&D (Kaitin, 
2010). Additionally, less than 25% of 
promising biomedical discoveries result in 
published clinical trials and less than 10% 
become established in clinical practice 
within twenty years (Drolet & Lorenzi, 2010). 
Many stakeholders consider there to be a 
fundamental problem with the prevailing 
blockbuster model of drug development. An 
industry respondent, for example, stated:
…there isn’t a good business model 
for the current paradigm [blockbuster 
drug discovery and marketing to large, 
undiff erentiated patient populations] 
… people who think there will be phar-
maceutical companies in 10 years’ time 
doing what they do today I believe are 
seriously mistaken, and you can see 
that the stock markets to a large degree 
agree with that position … individual 
companies with other areas of com-
mercial activity are also reducing their 
investment in pharmaceuticals … I 
don’t think there is a [shared] business 
model of how we’re doing things along 
the whole R&D pathway … we need to 
understand mechanisms, we need to 
understand the patients that we give 
our products to, and only then can we 
create any kind of product. (IND3) 
Th e notion of a broken drug innovation 
system has also been discussed in a number 
of reports by scientifi c organisations 
(AMS, 2011; Cooksey, 2006), regulatory 
agencies (FDA, 2006) and funders of 
medical research (MRC, 2008; NIH, 2010; 
NIH, 2011), which refl ects the diverse 
set of interests and systemic issues at 
stake, so this should not be considered 
merely a concern of the multinational 
pharmaceutical industry. All tend to agree 
that there are entrenched problems in the 
middle stages of R&D requiring support 
for greater ‘translational activities’ and 
the development and uptake of new tools 
to enhance drug discovery, development 
and regulatory processes. A key issue 
identifi ed in these reports, and a canonical 
theme in much of the TM literature, is the 
identifi cation and validation of ‘biomarkers’ 
to facilitate drug development and delivery, 
which will be discussed in more detail later. 
Central to many of these discourses are 
imagined futures in which the exploitation 
of technologies within a new TM framework 
contributes to solving the current challenge 
of a broken R&D system and brings benefi t 
to industry, patients and broader society in 
terms of improved therapies and economic 
return on innovation. Indeed, there are a 
number of drivers and strategic priorities 
for TM being put into practice by diff erent 
constituencies, each with their own 
expectations and notional ideas of value 
and benefi t. Th ese should not, as many 
authors have argued, be simply discounted 
as hype (Morrison & Cornips, 2012; Brown 
et al., 2000).
Industry, Academic and Policy 
Drivers and Expectations for TM
As both a general overarching philosophy 
and set of concrete practical activities, TM 
has acquired increasing status in academic 
medicine, the biopharmaceutical industries 
and policy/regulatory communities to 
capitalise on life science investments; 
contribute to what is now considered a 
growing knowledge-based bioeconomy 
(OECD, 2009); and provide tangible benefi ts 
in terms of safe and eff ective therapies for 
unmet medical need. Casting a more critical 
gaze on such narratives, we can observe 
diff erent notions of present and future 
value being mobilised across nuanced 
scientifi c, clinical, commercial and political 
landscapes. To be sure, despite enormous 
investment in resource, infrastructure and 
training; there is, as we shall see in the next 
109
section, little consensus on the defi nitional 
and conceptual boundaries of TM; its scale, 
scope and role in clinical practice; and what it 
can realistically deliver. Th is is partly a result 
of diff erent TM practitioners using the term 
in a variety of institutional and professional 
contexts, such that a simple, unifi ed vision 
of its key aims, objectives and ultimate goals 
is yet to emerge. Lack of consensus may 
become a problem if incompatible visions 
and expectations (Borup et al., 2006), based 
on unrealistic assumptions about bench to 
bedside research, become entangled within 
emerging institutional and organisational 
structures. It is also important to reiterate 
that many of the practices underpinning 
TM are not new, but simply a recasting of 
conventional historical practices, as the 
examples provided earlier  testify. But there 
are essentially three key constituencies 
pushing a broad TM agenda.  
For the biopharmaceutical industry 
concerned about phase 2 attrition rates, TM 
has acquired several meanings and driven 
a range of organisational and management 
strategies. Th ere are now TM units within 
most major pharmaceutical fi rms. In some, 
TM groups facilitate direct connection 
between basic research and patient care to 
address key questions about how therapies 
will work in the clinical setting. Th is is the 
‘patient-centred approach’ and includes 
attempts to perform fi rst-in-human studies 
much earlier in the development process, 
as described by Milne (2013). Firms have 
also tried to bridge the gap between late 
discovery and early clinical development 
to de-risk candidate selection and improve 
decision-making on what products to 
take forward into clinical trials. TM units 
have also served as conduits for accessing 
external knowledge, technologies and 
expertise through collaborations (Mittra, 
2007). Industry is essentially experimenting 
with various TM initiatives to improve the 
business of drug development, and respond 
to the pressures being placed on blockbuster 
drug discovery.
Academic science and clinical medicine 
are driving the TM approach ostensibly 
to exploit the range of new technologies 
emerging from life sciences and encourage 
communication and sharing of knowledge 
and expertise between the bench and the 
bedside, which are considered to have 
become too intuitionally and culturally 
distinct.  Many scientists and clinicians 
believe a gulf has emerged as a consequence 
of increasing specialisation on both sides, 
so TM is embraced as a mechanism to 
better coordinate and integrate research 
and clinical activities. Th e resurgent interest 
in the role of the ‘clinician-scientist’ (a 
professional equally adept at working in the 
lab or the clinic) is indicative of this broader 
concern about the lab/clinic interface 
(Wilson-Kovacs & Hauskeller, 2012). Th e 
academic and clinical sectors have built 
hopes and expectations around a particular 
vision of TM that they hope will help 
improve understanding of key mechanisms 
of disease and diagnostic procedures. Th is 
contrasts with the more narrowly focused 
commercial expectations of industry. 
A senior academic clinician that was 
interviewed described the academic drivers 
and interests in terms of ‘practical problem-
solving driven by scientifi c curiosity’ (SC2). 
Finally, there are complex assemblages of 
social, regulatory and policy drivers of TM 
centred on the safety and cost-eff ectiveness 
of new drugs. TM is promoted by the policy 
community as a means to (1) facilitate 
innovation of novel therapies and improve 
standards of safety and effi  cacy, for instance 
through the use of biomarkers and new 
diagnostic testing; (2) improve the design 
and execution of clinical trials by utilising 
improved preclinical knowledge; and (3) 
contribute to the growing bioeconomy 
through investment in new innovative 
technologies and therapies. Consequently, 
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there has been substantial government 
and charitable investment in translational 
R&D in universities and other public sector 
organisations; particularly from the MRC 
in the UK and the National Institutes of 
Health (NIH) in the United States. Th e 
NIH’s $575m investment in the National 
Center for Advancing Translational 
Sciences (NCATS), with a remit to catalyze 
innovations in translational science to 
improve innovation in drugs, diagnostics 
and devices, is indicative of the science and 
policy community’s growing commitment 
to the fi eld (NIH, 2011). Indeed, one could 
argue more cynically that TM was pushed 
by the policy community as a means to 
channel public funds to downstream drug 
development processes without having to 
explicitly state as such, which would not be 
politically expedient. 
Th at there have been diff erent 
imperatives driving TM and strategies for 
implementing it, refl ects both the range of 
diff erent sectors’ needs and expectations, 
as well as their understanding and framing 
of the core problem.  Nevertheless, there 
appears to be consensus that a systemic 
problem exists in the middle stages of 
health R&D that requires new approaches in 
terms of science, technology, infrastructure 
and organisation. Indeed, a basic lexicon 
for TM has emerged, with the latest model 
expounding 3 distinct phases of translation. 
T1 refers to the translation of basic science 
into clinical effi  cacy and is focused on 
the early stages of drug discovery and 
preclinical testing. T2 refers to effi  cacy 
translated to clinical eff ectiveness, and 
focuses on the middle stages of R&D.  T3 
refers to eff ectiveness translated to health 
care delivery, so is very much rooted in late 
stage development (Dougherty & Conway, 
2008). Drolet and Lorenzi (2010) take this 
approach further by distinguishing a ‘zone 
of translation’ that is an intermediary 
between basic science and accepted clinical 
practice/overall societal health impact. For 
these authors, T1-T3 represents particular 
‘chasms’ in research progression along 
the bench-to-bedside continuum and 
translational research refers to those specifi c 
activities aimed at bridging the chasms. 
Although this is quite a linear description 
of TM, it highlights some of the diff erent 
sites and interstices of knowledge where 
practitioners believe better translational 
is required. It is with this general TM 
framework in mind, and understanding of 
what is driving the approach, that we can 
begin to explore practitioner narratives in 
more detail. 
Practitioner Narratives and 
the Diff erent ‘Framings of 
Translational Medicine
In this section, I analyse the underlying 
defi nitions and framings of TM from the 
perspective of diff erent TM practitioners, 
before exploring a specifi c and crucial focus 
of TM, namely the identifi cation and use of 
biomarkers. Th e value currently ascribed to 
biomarkers, and high expectations about 
their role in mitigating phase 2 attrition 
rates, further highlights the power of the 
broken middle argument. 
Th e defi nition of TM and its conceptual 
and practical boundaries is a topic of 
much debate within biomedical science 
and policy communities. Th e T1-T3 model 
simplifi es quite complex and diverse 
beliefs and understandings of the R&D 
challenge and appropriate scientifi c, 
clinical, regulatory, social and institutional 
responses. On defi nitions and boundaries, a 
number of views emerge from the scientifi c 
literature and interview accounts of key 
professionals, which map on to one or more 
aspects of the T1-T3 model. Defi nitions 
range from the specifi c to the general and 
111
can cover ‘organisational processes’ as well 
as ‘scientifi c application’. One interview 
respondent (head of the translational 
department of a major funding agency) 
argued that for his organisation, translational 
research is not area of science, but a process 
of bi-directional knowledge fl ow from 
fundamental research to application and 
back again. Note here again the implicit 
assumption of a distinction between basic 
and applied science that are temporally 
separate. Translational medicine, in contrast, 
is a sub-set of research focused on what 
has traditionally been called ‘experimental 
medicine’. It is interesting to note that the 
defi nition of experimental medicine, like 
TM, is also open to some debate. Some 
believe it should encompass epidemiology, 
whilst others think it should be limited 
to small patient studies, according to this 
respondent. Nevertheless, terms are used 
interchangeably by practitioners of TM and 
diff erent framings may cover organisational 
or institutional processes as well as specifi c 
applications of science and technology.  
Narrow Defi nitions/Framings of TM
Narrow framings of TM tend to emphasise 
the concept of ‘applied basic science’ and 
are often life science-focused.  For example, 
TM has been described as a process for 
determining treatment based on molecular 
biological characteristics (Saijo, 2002) or as 
the ‘translation of genomic and functional 
biology discoveries into clinical practice’ 
(Niederhuber, 2010: 1088). A common 
trend has been to reduce TM to a discrete 
set of genomics-based techniques and 
applications that can serve as a conduit for 
integrating diff erent types of knowledge and 
expertise at both the bench and the bedside. 
One senior academic interview respondent 
stated: ‘I think that the defi nition currently 
of translational medicine is probably DNA-
based or protein-based type of biomarker 
studies’. (SA7). Another senior academic 
emphasised the benefi ts of this narrow and 
clearly delineated defi nition when he stated:
I think in many ways translational med-
icine is a very murky term … I think that 
a narrower defi nition gives some clear 
goals and directives and ways of unify-
ing the academic and industrial com-
munity in partnership (SA5).
Here, the importance of clearly defi ned 
outcomes from academic-industry 
collaborations is presented as a key feature 
in scoping the boundaries of TM, which is 
very much an output or goal-oriented view 
of TM.
Th ere also appear to be some sector-
specifi c framings, with the pharmaceutical 
industry very much reducing TM to the 
process of commercial drug development. 
An interview respondent that heads a 
commercial clinical trial company gave 
the following account, which is very much 
rooted in a commercial bench-to-bedside 
notion of TM.
What we’re looking at is taking some-
thing that perhaps is defi ned at bench 
level in terms of a particular drug or 
something that targets a particular site 
and then that is developed through a 
whole range of processes to the point 
where it can be accepted as a poten-
tial drug target to work on through a 
pharmaceutical company, and then 
eventually into the clinical side. So the 
way that we would defi ne TM is taking 
something that is very much research-
oriented and translating that into a 
commercial product. (IND4) 
Similarly, another industry respondent 
stated that TM was simply:
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Translating experimental fi ndings in 
the laboratory through to clinical fi nd-
ings in the hospital setting … we’re try-
ing to develop drugs to treat established 
diseases and we need to predict what 
might happen in the clinic (IND1).
Responses from industry suggest it adopts a 
process-driven approach to TM with a clear 
commercial focus on improving effi  ciency 
of R&D and reducing phase 2 attrition. Th is 
narrative is rooted in the notion of a bench-
to-bedside continuum, and assumes that 
in the middle stages of a sequential R&D 
process there is a fundamental problem that 
needs to be fi xed.  
In contrast to this commercial view 
of translation, the clinicians framed TM 
predominantly in terms of using life 
science technologies to improve diagnosis 
and categorisation of disease. One senior 
clinical psychiatrist stated:
Th e studies we have done to identify 
genes in schizophrenia, bipolar dis-
order and depression can all be con-
sidered highly translational because 
they are aimed at identifying sub-pop-
ulations of psychiatric diagnoses to 
improve treatment studies … Our [cur-
rent] diagnostic categories don’t have 
any real biological validity. If genetic 
studies lead to clearer diagnoses in psy-
chiatry this will translate into better 
treatment studies. (SC1)
Th is account presents TM as invaluable 
for exploiting life science tools and 
technologies to better categorise clinical 
disorders and ultimately improve patient 
treatment, which was a recurrent theme in 
the accounts of both academic scientists 
and clinicians. 
Th ese narrow framings of TM prioritise the 
science, technology and clinical processes 
of TM, rather than the broader institutional 
and system-level dynamics that are perhaps 
more relevant to implementation and 
exploitation of new organisational models. 
Th ey also appear to reify the bench-to-
bedside continuum (with the conventional 
demarcation of basic and applied research), 
in the spirit of the T1-T3 model. Th ere is little 
or no emphasis on feedback loops from the 
clinic to the lab, or the parallel processes 
that can often be temporally and spacially 
disjointed in modern health innovation.  
Broader Framings and Emphasis on 
the “Bench-to-Bedside and Back Again” 
Process
Some authors consider the one directional 
bench-to-bedside approach to TM outdated 
and unhelpful. Instead, they defi ne TM as a 
two-way iterative process from bench-to-
bedside and back again, with knowledge, 
information and expertise continually 
shared between clinicians and lab scientists 
so that patient data can explicitly inform 
basic science (Ledford, 2008; Soderquest 
& Lord, 2010). Mankoff  et al. (2004) have 
argued that the uni-directional defi nition 
fails because animal and other experimental 
models are not truly representative 
of human pathology. Many interview 
respondents countenanced the view that 
a feedback loop from bedside to bench is 
crucial. An industry respondent stated:
First of all it goes both ways, because 
a lot of the stuff  that we have discov-
ered from doing this in humans [treat-
ing with experimental drug] was then 
translated back into the lab. It’s not uni-
directional. (IND5)
Similarly, a respondent from the policy 
community argued that this way of framing 
TM takes us away from crude, linear 
accounts of R&D. He stated:
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Th e translational medicine element 
that I think is really benefi cial is the 
fact that, rather than it being a linear 
process, there is this two-way feedback 
… the science is defi nitely being infl u-
enced by patient accessibility in appli-
cation. (POL4)
Rubio et al. (2010) have developed a broad 
working defi nition of TM, which emphasises 
multidirectional integration of basic 
research, patient-oriented research, and 
population-based research with the long-
term objective to improve public health. For 
these authors, population-based research 
includes studies involving epidemiology, 
as well as social and behavioural sciences, 
public health equality evaluation and cost-
effi  ciency. Th e US NIH (National Institutes 
of Health, 2010) considers research that 
facilitates the use of best practice healthcare 
within the community and ensures cost-
eff ective treatment of disease an important 
component of TM, which goes slightly 
beyond the T3 phase of translation.  Here, 
we are beginning to get towards a fuller and 
more systemic account of translation. As 
one academic scientist stated:
My understanding of translational 
medicine is converting fundamental 
biomedical discoveries into practical 
solutions for health problems. Mostly 
it’s in the form of drugs, but it’s also in 
terms of policy and other things. So, 
the discovery that smoking is bad for 
your health was a major translational 
achievement where somebody’s fun-
damental epidemiological studies fol-
lowed up by some animal experimental 
studies clearly indicated that smoking 
was bad for your health, and was per-
haps the major component of lung can-
cer. And that’s been reinforced over the 
years and given rise to policy change, 
which has given rise to measurable ben-
efi t. Th at’s an example of translation in 
the policy fi eld. (SA6)
Th is account exemplifi es the broader 
institutional policy dimension and 
presents TM as about much more than the 
conventional drug development pipeline 
model. 
Th is range of views suggests that TM 
should be characterised as a general 
organising principle, or ‘social technology’ 
in Nelson and Sampat’s terminology, to 
drive the development of new scientifi c 
methods and technologies, innovation 
strategies and collaborative institutional 
arrangements to better bridge or integrate 
basic and clinical science and facilitate 
knowledge and information transfer from 
bench to bedside and, crucially, back again. 
However, even if we consider TM in this 
broadest sense, the question still arises as 
to whether there is anything novel in the 
current practices based on the ‘bench-
to-bedside and back again’ philosophy, 
and whether the very distinctions made 
between basic and applied phases of R&D 
adequately refl ect the messy realities of 
contemporary life science innovation and 
the challenges that lie therein.
Th e ‘Novelty’ of TM Practices in the 
Context of the Bench to Bedside ‘Problem’ 
As was discussed earlier, the conventional 
view of basic and applied science, and the 
caricatured accounts of bench-to-bedside 
relations that are used to present TM as 
novel and cutting edge, are largely based 
on a misrepresentation of the history of 
clinical medicine and the professional 
and institutional boundaries between 
laboratory and clinic, as a number of 
authors have nicely illustrated (Hoonaard, 
2009; Martin et al., 2008; Stokes, 1997; Sturdy 
2012). Sturdy, for example, argues that the 
tensions and confl icts between clinicians 
and bench scientists are often overstated 
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in historical accounts, which implies that 
the problem of a broken middle has also 
perhaps been overstated, or provided only 
a partial account of the health innovation 
challenge. Indeed, many of the barriers to 
successful health innovation, particularly in 
the context of novel life science innovation, 
are broad and systemic, such as the impact 
of regulation, markets and clinical uptake 
on innovation strategies (Tait, 2007, Mittra, 
2008; Mastroeni et al., 2012). From this 
perspective, a TM approach focused only on 
a particular set of technology and knowledge 
integration problems in the middle stages of 
the drug pipeline will not be suffi  cient.  
 Similarly, Martin et al. (2008) draw on 
the concept of ‘communities of promise’ 
to help us think more critically about the 
supposed new confi gurations between 
basic research and the clinic that coalesce 
around particular socio-technical objects. 
Using stem cells as a case study, the authors 
point to the ways in which narratives are 
often structured around expectations about 
how clinical developments emerge and 
idealised assumptions about the distinctive 
roles of basic science, clinical science and 
the commercial sector. Th e discourse of 
‘translation’, according to the authors, has 
thrown into sharp relief the ‘more complex 
and dynamic relationship between the 
spaces and communities of science and 
application in the clinic’ (Martin et al., 2008: 
30). 
 Interestingly, a number of interview 
respondents also had quite a critical and 
nuanced view of the putative novelty 
of TM. For example, most respondents 
agreed there has been a re-branding of 
conventional scientifi c and clinical practice 
in the drive to secure research funding 
from a policy community that has become 
enamoured by the rhetoric of ‘translation’, 
or has at least been using it to justify public 
investment in drug development. Some 
respondents expressed concern that TM 
is defi ned so broadly that it can essentially 
cover anything that is broadly applied basic 
science. A respondent from the NHS, for 
example, stated: ‘Th ey’re buzz words; I used 
to call it applied research’ (NHS 1). A senior 
academic scientist stated:
I’m not so sure it’s novel because there 
have always been people pursuing 
translational research. Really what it’s 
refl ective of is an eff ort to brand some-
thing and use that brand to catalyse 
the movement of discoveries of basic 
research into clinical practice. (SA4)
Other respondents also emphasised 
that although the concept itself was not 
necessarily describing anything radically 
novel, it still had an important function in 
alerting the biomedical community to the 
signifi cance of the R&D challenge and the 
need to think of new ways to resolve them 
at the scientifi c, clinical, technological and 
policy levels. It is important to note here 
that those who see TM as a re-branding 
exercise do not deny that the conventional 
innovation pathway is broken and needs 
fi xing in some fundamental sense. 
So, despite competing views about the 
role and scope of TM, and the fact that many 
of the practices underpinning TM are not 
novel in and of themselves, there has clearly 
been growing interest in eff orts to infl uence 
bedside-to-bench relations and much 
institutional resource and infrastructure 
(both public and commercial) dedicated 
to fi xing what is considered to be a broken 
middle of health R&D. In recent years, 
biomarkers have become an emblematic 
feature of this TM agenda and are generating 
powerful promissory discourses. I will now 
critically explore the nature and growing 
role of biomarkers and the underlying 
assumptions made about the current 
innovation pathway model. 
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The Promissory Role of Biomarkers 
as a Translational Technology 
A biomarker is any objective, measurable 
indicator of a biological state or process. 
Th e value of a biomarker is linked to its 
ability to facilitate understanding of disease 
mechanisms/pathways or therapeutic safety 
and effi  cacy. Some conventional biomarkers 
are relatively simple and well established 
within the clinic, such as cholesterol as 
a biomarker for risk of coronary heart 
disease, or blood pressure as a biomarker 
for hypertension, but a number of novel 
molecular biomarkers have been identifi ed 
since the mapping of the Human Genome. 
Although there has been a focus on complex 
molecular or biochemical biomarkers, there 
has also been signifi cant innovation in 
non-invasive imaging biomarkers, such as 
anatomical and functional imaging (Weber, 
2006). Many diff erent kinds of biomarkers 
are now being identifi ed, and translational 
studies are trying to validate new biomarkers 
to improve knowledge and understanding 
of disease, clinical decision-making and 
drug development processes.
Biomarkers have become a central theme 
in discussions about the role and long-term 
value of TM. Th ey are treated as almost 
synonymous with TM as they are considered 
relevant both to industry attempts to reduce 
phase 2 attrition rates and academics and 
clinicians hoping to improve understanding 
of disease mechanisms and patient 
outcomes. Biomarkers with associated 
diagnostic tests are also crucial to the 
development of stratifi ed medicine, which 
is currently high on the agenda of both 
commercial pharmaceutical companies and 
healthcare providers as a way of targeting 
therapies more eff ectively (Mittra & Tait, 
2012). Furthermore, some practitioners 
believe that biomarkers provide concrete 
foci for cross-sector and interdisciplinary 
TM collaborations, which are perhaps easier 
to manage than projects built around more 
ephemeral and vague areas of translational 
science, a view supported in the following 
account from a clinician:
I think it’s [biomarkers] a critical area 
certainly, and it’s one that universities 
and medical schools can get engaged 
with relatively simply. Whereas the late-
phase clinical trials are much more dif-
fi cult for us to be engaged in. (SC2)
In general, the senior academic scientists 
were optimistic about the potential role 
and signifi cance of biomarkers. In some 
accounts, biomarkers were implicitly 
framed as a progressive innovation that will 
come to replace many of the conventional 
clinical practices currently relied upon, as 
the following response nicely illustrates. 
Molecular biomarkers will replace a 
lot of conventional diagnostic tests, 
inevitably. Cancer at the moment is 
still defi ned, subdivided and graded by 
pathologists looking down microscopes 
… all of this diagnosis has to change in 
the next 20 years; it’s still arcane. (SA7) 
Here, biomarkers are imbued with a great 
deal of promissory clinical value that will 
enable scientists and clinicians to replace 
the old, subjective and imprecise methods 
of the pre-genomic era. Another interview 
respondent, from a funding agency, 
countenanced this view when he talked 
about biomarkers being of particular value 
to the fi eld of psychiatry. He argued that 
current diagnostic methods for psychiatric 
disorders are inadequate, because there is 
often a constellation of complex symptoms 
and the diagnostic categories are largely 
based on subjective judgements. Here, 
molecular biomarkers are considered 
to provide a more robust and objective 
measurement of disease state. 
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In contrast to scientists and clinicians’ 
primary interest in biomarkers as a means 
to improve classifi cation and diagnosis 
of disease, industry’s interest lies in their 
potential to identify safety or effi  cacy 
issues in the middle stages of R&D such 
that cost-of-failure in phase 2 and phase 
3 clinical trials can be reduced. Here, the 
value of biomarkers is inextricably linked 
to the notion of a broken middle of R&D. 
Th is industry narrative  provides a more 
pragmatic and tightly defi ned role for 
biomarkers, and has recently been used to 
justify industry participation and growing 
investment in various pre-competitive 
biomarker partnerships and consortia, 
including in the United States a major 
public-private Biomarkers Consortium, 
which is managed by the Foundation for the 
NIH (http://www.biomarkersconsortium.
org/).  
Th ere is additional interest in the 
potential for biomarker data to be used 
in regulatory decision-making, both to 
provide surrogate-endpoints for clinical 
trials and to select patients for clinical 
studies. Th is particular application is not 
being driven solely by the pharmaceutical 
industry. Regulators, such as the FDA, 
have outlined a commitment to the 
identifi cation and validation of biomarkers 
and innovative clinical trial design to drive 
forward pharmaceutical innovation (FDA, 
2006), and similar approaches are being 
considered by the European Medicines 
Agency (EMA). Th e FDA has also established 
an initiative to facilitate the development of 
biomarkers and ensure that regulations for 
the associated diagnostic tests are fi t for 
purpose (FDA, 2011), which is indicative 
of regulators’ growing expectations for the 
technology.
While it is clear that biomarkers are being 
embraced by a number of diverse actors 
and organisations involved in biomedical 
research and innovation, it is important to 
subject these promissory narratives and 
expectations to critical analysis, and also 
consider the assumptions that this focus on 
biomarkers makes about the nature of the 
health innovation pathway.
Limitations of Biomarkers and 
Underlying Assumptions about the 
Broken Innovation Pathway Model
Th e broken middle of health R&D is a 
powerful narrative that has driven TM 
strategies within industry, academia and the 
policy community. Biomarkers, I argue, have 
become a central focus in discussions about 
TM and have generated high expectations 
and future-oriented visions of a biomarker 
led diagnostic and drug discovery platform 
that will solve a number of R&D challenges. 
However, we must consider whether 
translational activities such as biomarker 
discovery and validation are based 
on untested and perhaps unrealistic 
assumptions about the transformative 
impact they are likely to have on the 
development of diagnostics and therapies 
in the short-term. Some interview 
respondents cautioned against fetishising 
biomarkers as a panacea for the broken 
innovation system. One academic scientist, 
specialising in haematology, described 
how biomarkers for indicating the fragility 
of plaque are considered the ‘Holy Grail’ 
within his fi eld. Basically, scientists want 
to understand when plaque is about to 
rupture and have developed a number of 
techniques to try and identify this in real 
time. He claimed that scientists have tried 
to measure markers in the blood stream, 
such as metalloproteinases that are shed 
from the plaque. Th ey have also used 
imaging techniques to visualise the plaque 
and see if it ‘lights up’ with a PET (Positron 
Emission Tomography) ligand, which would 
be indicative of very active plaque and a 
potential target for a therapy. However, the 
respondent added the following crucial 
caveat:
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Th ese approaches sound quite mature 
and well thought out but what they 
don’t address is the fact that there are 
hundreds of plaques in the average vas-
culature, and some of them are vulnera-
ble and some of them not, and what you 
see really is an aggregation of all these 
things, and if you were trying to fi nd 
the plaque that killed you, you’d be on a 
hiding to nothing. So it’s helpful, but not 
as helpful as people would try to make 
out. (SA2)
Incomplete knowledge about biomarkers, 
and a tendency to grant them special 
status in clinical decision-making and/
or commercial drug development 
programmes, can also lead to false 
conclusions about process and outcomes. 
Th e respondent continued to state:
Let me give you the example of oestro-
gen. If you give it as hormone replace-
ment therapy [trials  have shown] it 
lowered LDL cholesterol, it raised HDL 
cholesterol, it did a host of other things 
in the artery wall that you would have 
said, right, this is absolutely cast-iron, 
we’re ok here, we’ll get benefi t … At the 
end of the day, oestrogen caused more 
heart disease, and the biomarkers 
would have driven this in entirely the 
wrong direction … I think we’re decades 
away from having enough biomarkers 
to understand the entirety of the pro-
cess, and then aggregating them is very 
diffi  cult. (SA2)
Th ese accounts run counter to the more 
optimistic and transformative views of the 
use of biomarkers in drug development 
and diagnosis. Th e underlying complexity 
of disease processes and treatment eff ects, 
from this more sceptical perspective, 
renders biomarker studies so far insuffi  cient 
as a replacement for conventional 
clinical studies and outcome measures. 
Th e promissory and sanguine vision of 
a biomarker-led drug development and 
therapy paradigm is therefore very much a 
projected future; one that must overcome 
current technological reality and clinical 
complexity. Th is has implications for 
their more general and extended use in 
regulatory decision-making for clinical trials 
and clinical practice, which continues to be 
anchored to the conservative and cautious 
‘big pharma model’ of drug development 
(Tait, 2007).
 In their paper on gene mapping, 
Terwilliger and Goring (2009) provide 
a compelling argument that many 
future strategies around genomics have 
been made on unrealistic and untested 
assumptions about what the technology can 
realistically deliver. Th is argument would 
seem to apply equally to biomarkers and 
perhaps TM more generally. Th e diverse, 
and sometimes contradictory, views of 
interview respondents about the benefi ts 
and limitations of biomarkers would 
suggest that these technologies may work in 
some fi elds but not necessarily others. For 
example, biomarkers might facilitate better 
characterisation, diagnosis and treatment 
of certain cancers, but may not be so helpful 
in other areas (diabetes for instance), where 
there might be 30 known markers that only 
slightly raise the risk level. In the latter case, 
we must question the real underlying power 
of this new technological tool. 
So, while biomarkers do promise a 
number of solutions to the purportedly 
broken conventional model of drug 
innovation, there is a clear danger in 
fetishising one technological solution 
and ignoring broader systemic challenges 
and constraints. Furthermore, this focus 
on biomarkers, which from an industry 
perspective is very much rooted in concerns 
about phase 2 attrition rates, does tend to 
assume a particular innovation pathway 
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model for drug development, with a 
chasm between basic and applied research 
being responsible for a lack of successful 
translation from bench to bedside. TM 
then emerges as the most obvious solution. 
However, as we have seen, the broken 
middle of R&D narrative is far more complex 
and contested, and the distinction between 
basic and applied research, or lab and 
clinic, is not as straightforward as is often 
presented. 
Conclusions
Th e data I have presented in this paper 
suggests that TM is more than a discrete 
set of technological instruments and 
mechanisms for exploiting the life sciences 
for therapeutic benefi t, and it is based on a 
number of shared assumptions about the 
nature of R&D and the current challenges 
of drug development, particularly phase 
2 attrition and a gap between the lab and 
the clinic. Conceptually, I have drawn 
on a broad literature around hopes and 
expectations, as well as some critical 
approaches to the linear model of R&D 
and conventional distinctions between 
basic and applied research, to analyse 
diverse practitioner accounts centred on 
defi nitional frameworks, drivers and the 
general framing of TM. Th e data reveal the 
complex and relatively fl uid defi nitional 
and conceptual boundaries that are 
employed by diff erent professionals as they 
envision various objectives and outputs for 
the fi eld. Driving these discursive narratives 
has been a particular set of perceived health 
innovation challenges, which I have referred 
to as the ‘broken middle’ of health R&D. 
Th is problem narrative has, I have shown, 
presupposed a particular role and scope for 
TM – the centrality of biomarkers providing 
one key illustrative example. 
What has been demonstrated is that TM 
remains a relatively vague and ambiguous 
term, as diff erent practitioners delineate 
its role, scope and long-term value in a 
variety of diff erent ways. However, they all 
have in common a presumption that there 
is a problem in the successful transition 
of new technologies and therapies from 
the laboratory bench to the patient at 
the bedside and that a range of more 
translational activities will be critical to 
solving the innovation challenge. In this 
article I have taken a critical approach to 
both the conventional view of the ‘broken 
middle’ narrative and the notion that TM 
is a novel approach that truly transforms 
bench to bedside relations in ways that are 
historically unique. Th is, I suggest, is an 
untenable position and places far too high 
an expectation on TM. 
Instead, it is worth considering TM 
as both a general philosophy for ‘doing 
applied science’ in the context of new life 
science, and a diverse set of scientifi c and 
clinical activities orchestrated within new 
institutional settings and confi gurations. 
Indeed, despite TM being a rather murky 
and messy term, it has engendered tangible 
new opportunities and strategies for 
therapy development. Th is can be seen 
in the very real policy commitment to 
building new resource and infrastructure 
in the spirit of TM. Substantive cross-
sector collaborations, particularly between 
academia and the pharmaceutical industry, 
have been brought about as a result of 
this emerging TM agenda.  Th ere has also 
been an increasing role of public sector 
fi nance and expertise in downstream 
drug development in both the UK and 
globally.  Th ere are many examples of such 
initiatives. In the Netherlands, there has 
been the Center for Translational Molecular 
Medicine (CTMM), which involves multiple 
public sector and commercial research 
and clinical organisations collaborating 
to develop technologies and tools for 
personalized medicine (http://www.ctmm.
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nl/pro1/general/home.asp). In the United 
States, there is the heavily resourced NCATS 
initiative and the Biomarkers Consortium, 
which was discussed earlier. Th e UK 
Medical Research Council’s (MRC) launch 
of six translational medicine centres with 
funding of £15.5m in 2007, which were 
tasked with developing programmes with 
clear milestones to ‘overcome existing 
gaps or hurdles in translational science’ 
(MRC, 2007), is also indicative of this 
broad policy drive to invest in new kinds 
of approaches to biomedical research and 
therapy development. Th ese are just a 
few of the many hundreds of TM-inspired 
organisational changes that are arguably 
re-shaping the therapeutic R&D landscape, 
and reveal the transformative impact of 
the TM philosophy on institutional and 
organisational practices. Th is of course 
raises important issues around institutional 
constraints and the management of diff erent 
expectations about value and benefi t, which 
is beyond the scope of this paper.  
Nevertheless, TM’s key feature and 
enduring legacy might in the end be the 
reshaping of conventional approaches to 
the development and delivery of health 
innovation through a variety of changes in 
institutional and organisational practices. 
Indeed, it might be useful to consider 
TM as a new organising principle for 
health R&D, rather than something more 
bounded and tangible. If we accept this 
broad defi nition of TM as a kind of ‘social 
technology’, discussions about what TM 
is and what it can realistically deliver 
becomes less important than the question 
of how this amorphous concept is actively 
reshaping health innovation systems 
and the conventional everyday practices 
therein. Th is is not to deny that there are 
many challenges ahead. Th ere are policy 
challenges in terms of deriving long term 
health impacts as well as economic impact, 
which will take time to emerge. It is therefore 
important that consideration is given to the 
systemic features of TM and that attempts to 
institutionalise it in ways that will improve 
health innovation recognise relevant 
linkages (both enablers and constraints) 
along various health, innovation and 
policy/regulatory pathways. Th is requires 
an acceptance that the challenges facing 
life science-based therapeutic innovation 
have a broader systemic origin than those 
captured by the crude broken middle 
narrative and its assumption of linearity. 
Furthermore, expectations must be based 
on testable criteria and more robust 
evidence. Th is requires a means of better 
aligning the broader promissory futures 
expressed by certain TM advocates with the 
far more narrow goals of industry. 
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